Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $55.81 million. The enterprise value is $122.53 million.
Important Dates
The last earnings date was Friday, November 14, 2025, after market close.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Celularity has 28.33 million shares outstanding. The number of shares has increased by 13.94% in one year.
| Current Share Class | 28.33M |
| Shares Outstanding | 28.33M |
| Shares Change (YoY) | +13.94% |
| Shares Change (QoQ) | +9.69% |
| Owned by Insiders (%) | 12.11% |
| Owned by Institutions (%) | 13.87% |
| Float | 17.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.17 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.16
| Current Ratio | 0.16 |
| Quick Ratio | 0.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.35 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -25.03% |
| Return on Invested Capital (ROIC) | -45.74% |
| Return on Capital Employed (ROCE) | -99.48% |
| Revenue Per Employee | $329,902 |
| Profits Per Employee | -$655,667 |
| Employee Count | 123 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 6.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.50% in the last 52 weeks. The beta is 0.78, so Celularity's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -1.50% |
| 50-Day Moving Average | 1.94 |
| 200-Day Moving Average | 2.12 |
| Relative Strength Index (RSI) | 55.05 |
| Average Volume (20 Days) | 66,346 |
Short Selling Information
The latest short interest is 613,266, so 2.16% of the outstanding shares have been sold short.
| Short Interest | 613,266 |
| Short Previous Month | 630,932 |
| Short % of Shares Out | 2.16% |
| Short % of Float | 3.58% |
| Short Ratio (days to cover) | 4.48 |
Income Statement
In the last 12 months, Celularity had revenue of $40.58 million and -$80.65 million in losses. Loss per share was -$3.35.
| Revenue | 40.58M |
| Gross Profit | 20.54M |
| Operating Income | -48.67M |
| Pretax Income | -80.65M |
| Net Income | -80.65M |
| EBITDA | -41.36M |
| EBIT | -48.67M |
| Loss Per Share | -$3.35 |
Full Income StatementBalance Sheet
The company has $120,000 in cash and $66.76 million in debt, giving a net cash position of -$66.64 million or -$2.35 per share.
| Cash & Cash Equivalents | 120,000 |
| Total Debt | 66.76M |
| Net Cash | -66.64M |
| Net Cash Per Share | -$2.35 |
| Equity (Book Value) | -20.09M |
| Book Value Per Share | -0.71 |
| Working Capital | -54.72M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.56 million and capital expenditures -$91,000, giving a free cash flow of -$6.65 million.
| Operating Cash Flow | -6.56M |
| Capital Expenditures | -91,000 |
| Free Cash Flow | -6.65M |
| FCF Per Share | -$0.23 |
Full Cash Flow StatementMargins
Gross margin is 50.61%, with operating and profit margins of -119.95% and -198.75%.
| Gross Margin | 50.61% |
| Operating Margin | -119.95% |
| Pretax Margin | -198.75% |
| Profit Margin | -198.75% |
| EBITDA Margin | -101.91% |
| EBIT Margin | -119.95% |
| FCF Margin | n/a |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.94% |
| Shareholder Yield | -13.94% |
| Earnings Yield | -144.29% |
| FCF Yield | -11.89% |
Analyst Forecast
The average price target for Celularity is $6.00, which is 204.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 204.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Feb 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Celularity has an Altman Z-Score of -13.24 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.24 |
| Piotroski F-Score | 1 |
